In a bid to expand its oncology franchise, Bristol Myers Squibb (BMS) has agreed to acquire Mirati Therapeutics for US$58 per share in cash. Through the deal, which is worth up to US$5.8 B in total, BMS picks up access to Krazati (adagrasib), a KRAS-G12C inhibitor approved in the US for the treatment of second line advanced non-small cell lung cancer as well as a pipeline of targeted oncology candidates. The deal comes at a crucial time for BMS as its three leading drugs - Eliquis, Revlimid and Opdivo - reach their patent expirations within the next decade.